Staffing and Research Support Payments. CFFT will make the payments to Vertex specified below during 2004 and 2005 in support of the Research Program under this Agreement. [***] [***] [***] [***] [***] [***] Vertex will dedicate a minimum average [***] during its term, [***] Unless otherwise agreed in writing by CFFT, from and after the earlier of the date upon which Vertex notifies CFFT of its selection of a Primary and an Alternate Program, Vertex will devote [***] to the Alternate Program, and will apply [***]. Subject to the foregoing requirements, the research support specified above can be allocated as Vertex may determine in good faith between in-house and outside resources, between the Primary Program and the Alternative Program, and between and among individual budget line items.
Appears in 4 contracts
Samples: Research, Development and Commercialization Agreement (Royalty Pharma PLC), Research, Development and Commercialization Agreement (Royalty Pharma PLC), Research, Development and Commercialization Agreement (Royalty Pharma PLC)
Staffing and Research Support Payments. CFFT will make the payments to Vertex specified below during 2004 and 2005 in support of the Research Program under this Agreement. [***] [***] [***] [***] [***] [***] Total $21.281 Vertex will dedicate a minimum average [***] during its term, [***] Unless otherwise agreed in writing by CFFT, from and after the earlier of the date upon which Vertex notifies CFFT of its selection of a Primary and an Alternate Program, Vertex will devote [***] to the Alternate Program, and will apply [***]. Subject to the foregoing requirements, the research support specified above can be allocated as Vertex may determine in good faith between in-house and outside resources, between the Primary Program and the Alternative Program, and between and among individual budget line items.
Appears in 1 contract
Samples: Research, Development and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)